In August 2011, the anti-CD30 ADC brentuximab vedotin obtained accelerated approval for the treatment of relapsed HL after that phase 2 studies in HL patients relapsing after autologous hematopoietic stem cell transplantation (auto-HSCT, n = 102] and in systemic ALCL (n = 58) showed high overall response rates (ORRs; HL, 75%; ALCL, 86%) and complete response (CR) rates (HL, 34%; ALCL, 33%) [68–70]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.